{
    "name": "methoxy polyethylene glycol / epoetin beta",
    "comment": "Rx",
    "other_names": [
        "Mircera"
    ],
    "classes": [
        "Hematopoietic Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/mircera-methoxy-polyethylene-glycol-epoetin-beta-342153",
    "pregnancy": {
        "common": [
            "Available data from published case reports and postmarketing experience with use in pregnancy are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Chronic kidney disease is associated with maternal and embryo-fetal risks",
            "There are no data on the presence of methoxy polyethylene glycol-epoetin beta in human milk, the effects on the breastfed child, or the effects on milk production",
            "However, endogenous erythropoietin is present in human milk"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, administration of methoxy polyethylene glycolepoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose"
                ]
            },
            {
                "type": "Clinical consideration",
                "description": [
                    "Pregnancy in women with chronic kidney disease has been associated with adverse outcomes (eg, hypertension, pre-eclampsia, miscarriage, premature birth, low-birth-weight, polyhydramnios, and intrauterine growth restriction)"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, administration of methoxy polyethylene glycolepoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of methoxy polyethylene glycol-epoetin beta in human milk, the effects on the breastfed child, or the effects on milk production",
            "However, endogenous erythropoietin is present in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Erythropoiesis-stimulating agents (ESAs) increase the risk of the death, myocardial infarction, stroke, and venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence"
            ],
            "specific": [
                {
                    "type": "Chronic kidney disease",
                    "description": [
                        "In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a Hgb <11 g/dL",
                        "No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks",
                        "Use the lowest dose sufficient to reduce the need for red blood cell (RBC) transfusions"
                    ]
                },
                {
                    "type": "Cancer",
                    "description": [
                        "Not indicated and not recommended for the treatment of anemia due to cancer chemotherapy",
                        "A dose-ranging study ended early owing to the increased deaths among patients receiving Mircera than another ESA",
                        "ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Uncontrolled hypertension",
                "PRCA beginning after treatment or other erythropoietin protein",
                "History of serious or severe allergic reactions"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "In controlled clinical trials of patients with CKD comparing higher hemoglobin targets (13-14 g/dL) to lower targets (9-11.3 g/dL), ESAs increased the risk of death, myocardial infarction, stroke, congestive heart failure, thrombosis of hemodialysis vascular access, and other thromboembolic events in the higher target groups; use caution in patients with coexistent cardiovascular disease and stroke (see Black Box Warnings)",
                "Increased mortality and/or tumor progression in patients with cancer",
                "Not approved for chemotherapy-induced anemia",
                "Caution in history of cardiovascular disease or HTN; control hypertension prior to initiating and during therapy",
                "Risk of HTN, encephalopathy early in treatment",
                "Seizures reported in chronic kidney disease patients participating in clinical studies; increase monitoring of these patients for changes in seizure frequency or premonitory symptoms",
                "Risk of developing treatment-associated antibodies (Abs) if: sudden loss of treatment response; severe anemia & low reticulocyte count",
                "Risk of developing pure red cell aplasia (PRCA) & severe anemia, with or w/out other cytopenias",
                "Evaluate for PRCA if lack/loss of response to Micera develops, in absence of other etiology; if severe anemia and low reticulocyte count develop during treatment, withhold therapy and evaluate for PRCA",
                "Not for use as substitute for RBC transfusions in patients who require immediate correction of anemia",
                "Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, tachycardia, pruritus skin rash, urticaria, and Stevens-Johnson syndrome/toxic epidermal necrolysis reported; if serious allergic or anaphylactic reaction occurs due to therapy, immediately and permanently discontinue treatment and administer appropriate therapy",
                "Blistering and skin exfoliation reactions including erythema multiforme and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN), in the postmarketing setting; discontinue therapy immediately if a severe cutaneous reaction, such as SJS/TEN, is suspected",
                "Patients may require adjustments in their dialysis prescription after initiation treatment; patients may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypertension",
            "percent": "13"
        },
        {
            "name": "Diarrhea",
            "percent": "11"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "11"
        },
        {
            "name": "Headache",
            "percent": "9"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "9"
        },
        {
            "name": "Muscle spasms",
            "percent": "8"
        },
        {
            "name": "Procedural hypotension",
            "percent": "8"
        },
        {
            "name": "Fluid overload",
            "percent": "7"
        },
        {
            "name": "Back pain",
            "percent": "6"
        },
        {
            "name": "Cough",
            "percent": "6"
        },
        {
            "name": "Vomiting",
            "percent": "6"
        },
        {
            "name": "Hypotension",
            "percent": "5"
        },
        {
            "name": "Urinary tract infection",
            "percent": "5"
        },
        {
            "name": "Arteriovenous fistula thrombosis",
            "percent": "5"
        },
        {
            "name": "Arteriovenous fistula site complication",
            "percent": "5"
        },
        {
            "name": "Pain in extremity",
            "percent": "5"
        },
        {
            "name": "Constipation",
            "percent": "5"
        },
        {
            "name": "Cases of pure red cell aplasia",
            "percent": null
        },
        {
            "name": "PRCA",
            "percent": null
        },
        {
            "name": "and of severe anemia",
            "percent": null
        },
        {
            "name": "with or without other cytopenias",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Toxic epidermal necrolysis",
            "percent": null
        }
    ]
}